The study, published in the Journal of Neuro-Oncology, tackles a problem that has grown more pressing as whole-brain radiation therapy has fallen out of favor. Brain metastases, the spread of cancer to the brain from tumors elsewhere in the body, are estimated to occur in a substantial fraction of patients with advanced cancer, and as systemic therapies extend survival, more patients live long enough to face complications in the brain itself. Modern guidelines from ASTRO, ASCO, and the Society for Neuro-Oncology favor stereotactic radiosurgery, which concentrates high radiation doses on individual tumors while sparing healthy tissue. But large lesions, defined in this study as those with a volume of at least 4 cubic centimeters, pose a special challenge. A single massive dose of radiation risks injuring surrounding brain tissue, so clinicians must choose between single-session treatment, splitting the dose into staged sessions weeks apart, or delivering it in a handful of larger-than-conventional fractions known as hypofractionation. Which strategy works best, and at what dose, has remained genuinely uncertain.

The research team, led by Yuta Koketsu and corresponding author Toshinori Hasegawa, took advantage of a decade of experience at a single Gamma Knife center. Between 2016 and 2024, they treated patients with large brain metastases using all three approaches, individualizing both the treatment schedule and the radiation dose to each patient’s anatomy and clinical situation. For the analysis, they focused on one dominant lesion per patient and tracked it with serial imaging. Radiographic progression was defined conservatively as an increase of at least 20 percent in the longest tumor diameter from its smallest recorded size, the nadir. But the investigators went a crucial step further than most radiographic studies. They distinguished true progression, meaning enlargement that persisted or forced the team to intervene with additional treatment, from pseudoprogression, in which a lesion that initially appeared to grow later stabilized or shrank on its own without any salvage therapy. This distinction matters enormously, because treating pseudoprogression with more radiation or surgery exposes patients to harm for a problem that would have resolved by itself.

The headline result concerns dose. Using the concept of biologically effective dose, a radiobiological formula that converts different dose-and-fractionation schedules into a single number reflecting the expected biological effect on tumor cells, the team found a clear threshold. Lesions that received a BED10 of at least 57.6 Gy had a significantly lower risk of true progression, with a subdistribution hazard ratio of 0.46, meaning the hazard was cut by more than half, and the difference was statistically significant at p equals 0.02. In practical terms, the BED10 framework rewards clinicians for thinking beyond the raw dose number on a treatment plan. A modest dose delivered in a single session and a larger total dose spread over several sessions can be biologically equivalent to tumor cells, and the 57.6 Gy threshold gives clinicians a common currency for comparing schedules. Notably, the analysis found that true progression rates did not differ significantly by treatment modality, whether single-session, staged, or hypofractionated, or by tumor volume, suggesting that what matters is the total biological punch delivered rather than the specific way it is packaged.

The cumulative incidence figures tell the story of what patients face over time. At six months after Gamma Knife surgery, 17.4 percent of lesions had undergone true progression. By twelve months, that figure had climbed to 31.5 percent, and by twenty-four months it had essentially plateaued at 33.1 percent. That plateau is clinically meaningful: it suggests that if a large treated metastasis is going to truly regrow, it almost always does so within the first year, and a patient who reaches the two-year mark with local control is unlikely to lose it. The median overall survival of the entire cohort was 15.3 months, which means that for a large share of these patients, the question of local tumor control is not academic; it unfolds within their actual lifespan and directly affects their quality of life and neurological function.

Of the 143 lesions followed, 47 eventually showed radiographic progression, but the breakdown reveals how treacherous imaging interpretation can be. Forty-two turned out to be true progression, four were pseudoprogression, and one was attributed to intratumoral hemorrhage. In other words, roughly one in ten radiographic failures was not a failure at all. The pseudoprogression phenomenon reflects radiation necrosis, a delayed injury to brain tissue in and around the treated lesion that can cause the enhancing area on MRI to enlarge, mimic tumor growth, produce mass effect and edema, and even bring back a patient’s original neurological symptoms. Biopsy series from other centers have repeatedly shown that enlarging lesions after radiosurgery frequently contain necrosis rather than viable tumor. The Komaki team illustrated the point vividly in a supplementary case: a man in his seventies with a 66 cubic centimeter occipital metastasis causing hemianopsia and Gerstmann syndrome received two-stage Gamma Knife treatment with 12 Gy per stage. His symptoms resolved and the tumor shrank dramatically, but a year later the lesion enlarged again with worsening edema and recurrent vision loss, apparently demanding salvage therapy. Instead, it stabilized on its own at eighteen months and the edema improved by twenty-two months, consistent with radiation necrosis running its natural course.

How, then, can clinicians tell the impostor from the real thing? The study’s most actionable finding is a timing signature. Recurrent peritumoral edema, the reappearance or worsening of fluid accumulation in brain tissue around the lesion, developed far earlier in true progression than in pseudoprogression, with a median of 173.5 days versus 564 days, a difference that was highly significant at p equals 0.001. When tumor enlargement and renewed edema arrive together within roughly the first year after treatment, the pattern strongly indicates genuine tumor regrowth, and the authors conclude that such a finding should prompt consideration of early salvage intervention rather than a prolonged wait-and-see approach. Conversely, enlargement with edema emerging well beyond the one-year mark is more consistent with late radiation necrosis, where observation may spare the patient unnecessary surgery or reirradiation. This simple temporal rule requires no advanced imaging, no perfusion sequences, no spectroscopy, and no biopsy, only careful attention to the calendar alongside the MRI.

The study also speaks to what happens when a lesion does fail and clinicians reach for a second round of Gamma Knife treatment. Among patients who underwent repeat radiosurgery, a lower marginal dose at the second session was associated with subsequent true progression, with a hazard ratio of 0.82 per dose increment, significant at p equals 0.02. The interpretation is sobering: underdosing at salvage treatment appears to invite another failure, yet pushing the dose higher raises the specter of radiation necrosis, particularly since the surrounding tissue has already been irradiated. Repeat stereotactic radiosurgery for recurrent brain metastases is well established in the literature, with systematic reviews and meta-analyses documenting both its efficacy and its necrosis risk, and the new data add a quantitative argument for dosing salvage sessions deliberately rather than timidly. The team notes that their institution has also explored combined approaches, including reirradiation followed by resection, for select recurrent lesions.

Why does dose matter so much biologically? The answer lies in classic radiation biology. Tumor cells vary in their oxygenation, and cells at intermediate oxygen levels can substantially influence the response of a tumor to fractionated radiotherapy, a relationship explored in foundational work by Wouters and Brown. Hypoxic cells require more radiation to kill, and fractionation schedules that allow tumor reoxygenation between sessions can partially compensate, which is precisely why the BED10 framework, which encodes the effect of fractionation, is a better predictor of control than the physical dose alone. Large metastases are also more likely than small ones to contain poorly oxygenated cores and to press against eloquent brain structures that force dose reductions, creating a tension between tumor control and toxicity that the 57.6 Gy threshold helps clinicians navigate quantitatively.

The study’s limitations are those inherent to its design: it was retrospective, conducted at a single institution, and treatment decisions were individualized rather than randomized, so selection biases cannot be fully excluded. Datasets are available from the corresponding author on reasonable request, and the work received no specific external funding. Still, the practical takeaways are hard to ignore. For patients with large brain metastases, the total biologically effective dose delivered to the tumor edge should be planned to reach at least 57.6 Gy BED10, using whatever fractionation scheme best protects the surrounding brain. And in follow-up, the pairing of tumor enlargement with recurrent peritumoral edema within a year of Gamma Knife surgery should be read not as an ambiguous radiological curiosity but as a call to act, because in this disease, waiting for certainty can cost patients the window in which salvage treatment works best.

Subject of Research: Dose selection and progression assessment after Gamma Knife radiosurgery for large brain metastases

Article Title: Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression

Article References: Koketsu, Y., Hasegawa, T., Kato, T., Naito, T., Mizuno, A., Ando, Y., Kosaka, N., & Saito, R. (2026). Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression. Journal of Neuro-Oncology, 180(1), Article 3. https://doi.org/10.1007/s11060-026-05792-0

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05792-0

Keywords: Gamma Knife surgery, stereotactic radiosurgery, brain metastases, biologically effective dose, pseudoprogression, radiation necrosis, peritumoral edema, salvage therapy, hypofractionation, tumor progression, radiation oncology, neuro-oncology

The central result is striking in its simplicity. Among the 100 enrolled patients, only 8 percent developed grade 2 acute genitourinary toxicity—defined in this trial as urinary frequency severe enough to require two or more medications—with a 95 percent confidence interval of 2.6 to 13.4 percent. Not a single patient experienced grade 3 or higher acute genitourinary toxicity, and no grade 2 or worse urinary retention, urinary pain, urinary urgency, or hematuria was recorded. Grade 1 urinary frequency, the mildest form, occurred in 46 percent of patients, but even this figure reflects a symptom burden that many patients with enlarged prostates already live with before treatment begins. No acute gastrointestinal adverse events were observed at all, a notable outcome given that rectal toxicity is often the limiting factor in prostate radiotherapy.

The radiobiological logic behind the regimen is what makes the result scientifically interesting. Prostate cancer cells carry an unusually low alpha/beta ratio—estimated at approximately 1.4 Gy—which describes how sensitive a tumor is to the size of each radiation fraction. A low alpha/beta value means the cancer is more vulnerable to large individual doses than the surrounding healthy organs are. Hypofractionation exploits this vulnerability: by delivering bigger doses per session, clinicians can inflict disproportionate damage on tumor cells while the nearby bladder and rectum, which have higher alpha/beta values, theoretically tolerate the schedule better. Conventional fractionated radiotherapy delivers 2.0 Gy per fraction across 38 to 40 sessions over nearly two months; the Japanese trial delivered 51.6 Gy in relative biological effectiveness terms across just 12 sessions in a median overall treatment time of 20 days, with no interruptions or delays in any patient.

Protons add a second layer of physical advantage on top of this radiobiological one. Unlike photon beams, which deposit radiation along their entire path through the body and exit on the far side, protons stop at a depth determined by their energy—the Bragg peak—releasing their maximum dose precisely at the tumor and falling off rapidly beyond it. This means minimal energy is deposited in normal tissue in front of the target and essentially none behind it. The trial used the IBA Proteus ONE system, a compact gantry with spot-scanning beam delivery, and planned treatments in RayStation version 10A using a single-field uniform dose algorithm applied to a beam-specific planning target volume, an approach shown to improve conformity and organ sparing compared with uniform-dose planning target volumes.

The technical preparation was equally meticulous. Before treatment, urologists implanted transperineal ultrasound-guided gold fiducial markers into each patient’s prostate and injected SpaceOAR, a hydrogel spacer that physically separates the prostate from the rectum, reducing the dose the rectal wall receives. Daily treatments began with image-guided bony alignment followed by fiducial-based registration, maintaining positional accuracy within a 1-millimeter margin. Patients were instructed to arrive with a comfortably full bladder and an empty rectum, immobilized supine on a vacuum pad. Simulation used 1-millimeter-thick CT slices fused with 3.0 Tesla MRI. The clinical target volume encompassed the prostate and, depending on risk group, part of the seminal vesicles—none for low-risk patients, the proximal third for intermediate-risk, and the proximal half for high-risk—expanded by 5 to 6 millimeters to form the planning target volume. Elective pelvic lymph node irradiation was deliberately omitted.

The trial’s design reflects a careful, staged approach to safety. Built on Simon’s minimax two-stage design with a significance level of 0.05 and 90 percent power, the protocol set acceptable and unacceptable toxicity thresholds at below 5 percent and above 15 percent respectively. In the first stage, 30 patients were enrolled; only two developed grade 2 genitourinary toxicity, satisfying the continuation criterion. In the second stage, the cohort grew to 83 patients with seven grade 2 events, again passing the checkpoint. A protocol-specified expansion then brought the total to 100 patients. Any grade 4 or 5 normal tissue toxicity would have mandated immediate suspension of the study, an event that never occurred. The researchers also adopted a modified grading system from earlier work by Nakajima and colleagues, because standard CTCAE version 5.0 criteria struggle to distinguish radiation-induced urinary symptoms from the baseline symptoms of benign prostatic hyperplasia, which many older prostate cancer patients already have. Under the modified criteria, one dysuria medication counted as grade 1 and two or more as grade 2.

Perhaps the most puzzling finding is a counterintuitive pattern in the subgroup analysis. Multivariate logistic regression revealed that high-risk patients—those with higher PSA levels, more advanced T stage, or Gleason scores of 8 or above—had a significantly lower likelihood of developing grade 2 genitourinary toxicity than lower-risk patients, with an odds ratio of 0.023 and a P value of 0.042. High-risk patients received both neoadjuvant and adjuvant androgen deprivation therapy, while intermediate-risk patients received neoadjuvant hormone therapy alone. One earlier hypothesis held that androgen deprivation shrinks the prostate and thereby reduces toxicity, but the intermediate-risk group, which also received hormone therapy, did not show the same protective pattern. The authors are candid that the mechanism behind this trend toward low toxicity in the high-risk group is unknown and warrants further investigation.

The analysis also confirmed benign prostatic hyperplasia as an independent risk factor for grade 2 genitourinary toxicity, with an odds ratio of 0.040 and a P value of 0.018. This aligns with clinical intuition: a gland already compromised by enlargement has less functional reserve when radiation inflames the urinary tract. The finding underscores why the modified grading criteria matter, since disentangling treatment effects from pre-existing conditions is essential for honest toxicity reporting. It also hints at a practical implication for future trials—baseline urinary function may need to be a stratification factor when comparing fractionation schedules across institutions.

How does this compare with photon-based alternatives? The evidence base for shorter prostate radiotherapy is already strong: randomized trials of hypofractionated and ultra-hypofractionated photon therapy, including the HYPO-RT-PC trial of ultra-hypofractionated treatment, have confirmed efficacy comparable to conventional schedules. But acute toxicity data have been less favorable. A pilot study of ultra-hypofractionated intensity-modulated radiation therapy delivering 54 Gy in 15 fractions reported acute grade 2 genitourinary toxicity in 21 percent of patients—more than double the 8 percent seen in the proton trial. Earlier proton work by Nakajima’s group using 60 to 63 Gy in 20 to 21 fractions reported a 5.9 percent rate, and carbon-ion radiotherapy studies using the same 12-fraction, 51.6 Gy regimen achieved rates of 3 to 4 percent. Because carbon ions and protons differ fundamentally in physical characteristics and biological modeling, the question of whether the carbon-ion schedule could be safely transplanted to proton therapy had lacked prospective evidence—until now. A related phase II effort by Iwata and colleagues reported a 6.3 percent incidence using similar modified criteria in a 300-patient proton cohort, closely mirroring the present result.

The study has acknowledged limitations. It was conducted at a single institution, and patients with severe baseline urinary symptoms were excluded, which ensures a clean read on radiation-induced toxicity but limits generalizability to men with poor baseline urinary function. The current report covers only acute toxicity within three months; late genitourinary and gastrointestinal effects, local control rates, and biochemical recurrence-free survival await the ongoing expansion cohort, which targets 300 evaluable patients. Still, the early signal is compelling: a three-week proton regimen that matches the safety profile of far longer schedules, spares the bowel entirely in the acute setting, and returns patients to their lives weeks earlier. If the long-term data hold, the combination of the Bragg peak’s physics, hypofractionation’s radiobiology, and hydrogel spacer technology may redefine what men can expect from curative prostate radiotherapy—fewer visits, fewer side effects, and no compromise on the medicine itself.

Subject of Research: Acute genitourinary toxicity of hypofractionated proton beam therapy for localized prostate cancer

Article Title: Analysis of acute genitourinary toxicity in hypofractionated proton beam therapy for localized prostate cancer

Article References: Yang, W., Mizoe, J., Osaka, Y., Miyabe, Y., Seki, H., Nakamura, H., Sugawara, H., Miyajima, N., Iwata, H., Hashimoto, T., & Komaki, R. (2026). Analysis of acute genitourinary toxicity in hypofractionated proton beam therapy for localized prostate cancer. Holistic Integrative Oncology, 5(1), Article 35. https://doi.org/10.1007/s44178-026-00246-z

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00246-z

Keywords: prostate cancer, proton beam therapy, hypofractionation, genitourinary toxicity, radiation oncology, Bragg peak, CTCAE, androgen deprivation therapy, benign prostatic hyperplasia, SpaceOAR, clinical trial, urinary frequency

The motivation is not academic. In a structured workshop where radiation oncologists, medical physicists, and technologists applied the same radiobiological models to the same standardized cases, mean agreement between practitioners reached only 25.8 percent on a Jaccard index, dropping to 10 percent for head-and-neck cases. Proposed dose-per-fraction adjustments for identical clinical situations ranged from 1.8 to 2.5 Gy, and nearly half of the surveyed centers reported they could not compute biologically equivalent schedules with the tools available to them. Multi-center studies of reirradiation have reached the same conclusion from another direction: variation in how centers scale radiobiological dose introduces clinically relevant differences in cumulative dose estimates.

Part of that dispersion reflects disagreement about vocabulary rather than radiobiology. Identical parameters yield substantially different reported EQD2 values depending on whether proliferation losses are applied to the evaluated schedule only or symmetrically to both the evaluated and the reference schedule. Three modeling elements are routinely omitted. First, the classic linear-quadratic model is widely held to overestimate cell kill at the large fraction sizes used in stereotactic treatments, so the linear-quadratic-linear form of Astrahan replaces the quadratic term with a straight line above a transition dose. Second, overall treatment time matters, because accelerated proliferation of surviving tumor cells after a kick-off time consumes dose every day, meaning an interruption is never neutral. Third, when two fractions are given in a single day, the incomplete-repair correction of Thames applies, since the second fraction arrives before sublethal damage has fully repaired.

The new release is a reimplementation of a validated 2014 MATLAB application, rebuilt as a dependency-free Python library and a browser application. The original was a Windows executable requiring a several-hundred-megabyte MATLAB runtime, with an interface in French and 3,567 lines of source in which the entire calculation sat inside a single callback. It could not be inspected, cited by version, or run by a colleague during a meeting. Version 3.0 separates the model, the calendar conversion, and a library of radiobiological tissue parameters into an auditable core that depends only on the Python standard library. The delivery layer embeds the sources into a single HTML page of about 112 kilobytes that runs the model locally in each visitor’s browser using WebAssembly, with no computation on a server, no analytics, and no forms.

The mathematics is deliberately complete. Each tissue carries seven parameters, including the alpha/beta ratio, a transition dose above which the response becomes linear, a repair half-time, and a kick-off time and doubling time for proliferation. The software computes biologically effective dose with the linear tail, subtracts proliferation losses once overall time exceeds the kick-off time, applies the incomplete-repair correction for twice-daily fractions, and then solves for the number of reference fractions carrying the same biological effect. Crucially, the reference schedule carries its own overall time and therefore its own proliferation loss, a point the authors identify as accounting for most disagreement between implementations. Treatment calendars run five days a week, weekends included, because cells do not rest on Saturdays, and successive courses are matched against one continuous reference schedule rather than restarting the clock each time.

Verification proceeded in two distinct steps. The first asked whether the calculation was transcribed correctly from MATLAB to Python: replaying 4,438 treatment schedules through the original 2014 program and the new library produced 69,131 compared values, of which 99.991 percent agreed at the reference’s own six-digit precision, with a largest single deviation of 0.04 Gy and every one of 34,403 paired equivalent doses clearing a pre-set tolerance of 0.05 Gy. The second step checked the equations against closed forms independently of the old code. The authors are careful to state that neither check constitutes clinical validation; both establish fidelity and correctness of the arithmetic.

One change between releases genuinely moves results. The 2014 code charged elapsed treatment time twice, once inside the equivalence equation at a flat rate and once afterward using the real calendar, which inflated organ doses for protracted schedules. Version 3.0 charges time once, on the calendar throughout. The magnitude is striking: for 60 Gy delivered at 12 Gy per fraction, the old treatment overstated lung equivalent dose by 74 percent, against 28 percent for the correct single charge. At the reference fraction size of 2 Gy the effect vanishes, and below it the sign reverses, with protracted schedules losing dose rather than gaining it. Four smaller defects of the old release, including a division by zero that reported complication probability as 100 percent for five tissues, were also fixed and documented rather than silently corrected.

External coherence checks place the tool against landmark trials. Against 78 Gy in 39 fractions, the software puts the ultra-hypofractionated arm of the HYPO-RT-PC prostate trial at 77.94 Gy, and it orders the two hypofractionated arms of CHHiP as the trial did. It disagrees with PROFIT, placing 60 Gy in 20 fractions 5.5 Gy below the conventional arm that demonstrated non-inferiority, but that gap closes when the alpha/beta ratio is set to 1.5 Gy, near the pooled clinical estimate of 1.4 Gy, evidence that the tabulated default of 3.1 Gy is not universal. On the normal-tissue side, the tabulated Lyman parameters fail outright for the spinal cord, returning a 5.1 percent complication probability where QUANTEC puts the risk near 0.2 percent, a discrepancy the authors report plainly.

The limitations are stated with unusual candor. This is a model comparison tool, not a treatment planning system: it knows nothing of dose distributions, volume effects, or plan constraints, and the authors explicitly warn that its outputs must not be used to choose or modify a prescription, compute compensation for a real interruption, sum dose in a reirradiation decision, or predict outcomes for an individual patient. The tumor control probability, newly exposed in this release, has not itself been validated against clinical outcome, and parameter uncertainties frequently exceed the differences the software displays, which is why it offers an alpha/beta sensitivity band and declines to name a best schedule when uncertainty bars overlap. Its purpose is comparing schedules under a stated model, seeing how the comparison moves when assumptions move, and teaching why.

The impact may ultimately lie in access and traceability. In a field where nearly half of surveyed centers report no usable tool, removing the installation barrier is the difference between a model being applied and being skipped. Every parameter’s provenance is recorded, the historical 2014 behavior remains reachable so that older published results can be reproduced, and the validation dataset ships with the code. A version-pinned, openly inspectable implementation that every participant in a multi-center study can run in a browser removes one term from the variance between centers, separating disagreement over arithmetic from the genuine scientific disagreement over parameters. A correction pushed to the repository goes live in browsers within a minute, and every version stays citable by its own DOI, an ambition the authors state explicitly: to give every department something independent against which to check a commercial planning system’s answer.

Subject of Research: Open-source software for biologically equivalent dose calculation in radiotherapy fractionation

Article Title: LQL-Equiv-web: a Python library and browser application for linear-quadratic-linear dose equivalence in radiotherapy

Article References: LQL-Equiv-web: a Python library and browser application for linear-quadratic-linear dose equivalence in radiotherapy. (n.d.). https://doi.org/10.1016/j.softx.2026.103085

Image Credits: AI Generated

DOI: 10.1016/j.softx.2026.103085

Keywords: radiotherapy, dose equivalence, EQD2, linear-quadratic model, hypofractionation, radiobiology, open-source software, WebAssembly, Python, treatment interruptions, reirradiation, tumor control probability

The meeting, led by ASTRO President Neha Vapiwala, MD, FASTRO, is expected to draw roughly 10,000 oncologists, clinicians, physicists, researchers and other health care professionals from around the globe. Its theme this year, “Data to Dialogue: Communicating Radiotherapy’s Value to Advance Care,” signals a deliberate push to translate dense clinical trial results into conversations that patients, policymakers and the broader public can actually use. The program includes keynote addresses from former U.S. Food and Drug Administration Commissioner Scott Gottlieb, MD, and the award-winning oncologist and bioethicist Ezekiel Emanuel, MD, PhD, along with expert panels on two of the most consequential frontiers in cancer medicine today: artificial intelligence and radiopharmaceutical therapy.

One of the most anticipated presentations is a ten-year outcomes report from a phase 3 randomized trial comparing hypofractionated versus conventional fractionated postmastectomy radiotherapy in high-risk breast cancer patients. Fractionation — the practice of dividing a total radiation dose into many smaller daily treatments — has been a cornerstone of radiotherapy for decades, but the standard schedule for patients who have undergone mastectomy has historically been longer than for those who had lumpectomy. Hypofractionation compresses treatment by delivering larger doses per session over fewer visits, and long-term phase 3 data in the postmastectomy setting could reshape how clinicians counsel tens of thousands of women each year about the trade-offs between convenience, toxicity and cancer control.

The breast cancer theme continues with a study that addresses a different kind of gap: not biological, but logistical. The Navigator-Assisted Hypofractionation program, known as NAVAH, examined the impact of patient navigation within a cancer center-community partnership on access to short-course radiation therapy for African-American breast cancer patients. Shorter hypofractionated courses reduce the burden of daily travel, missed work and childcare conflicts — burdens that fall disproportionately on under-resourced patients — yet adoption has lagged in exactly the communities that stand to benefit most. Early results from this program, presented by Afua Ofori-Darko, BS, MPH, offer a test of whether structured navigation and community partnerships can close that gap, an approach that aligns squarely with the meeting’s “Data to Dialogue” theme.

Liver cancer takes center stage in two separate highlight abstracts. The first is the initial results of NRG-GI003, a phase III randomized trial from NRG Oncology comparing protons with photons — that is, proton beam therapy versus conventional X-ray-based radiotherapy — for hepatocellular carcinoma, the most common form of primary liver cancer. Proton therapy has long been promoted on theoretical grounds: protons deposit most of their energy at a precise depth and stop, sparing healthy tissue downstream of the tumor. In the liver, where patients often have compromised organ function and limited reserve, that dosimetric advantage could translate into meaningful clinical differences. Whether those physics advantages hold up as survival and toxicity outcomes in a rigorous randomized comparison is precisely the question NRG-GI003 was designed to answer, with results presented by Theodore Hong, MD.

A second liver cancer study, from a Chinese research group led by Lihong Wang, MD, tackles an earlier stage of disease. In an interim analysis of a prospective, single-center, non-inferiority randomized clinical trial registered as ChiCTR2000039404, researchers compared stereotactic body radiation therapy, or SBRT, against radiofrequency ablation for small hepatocellular carcinomas measuring two centimeters or less. Radiofrequency ablation has been a standard local treatment for small liver tumors, but it has limitations: tumors in difficult locations may be incompletely treated, and the technique’s effectiveness can depend heavily on tumor position and operator skill. SBRT delivers highly focused, ablative doses of radiation in just a few sessions, and a randomized non-inferiority comparison against ablation could establish radiation as an equally valid first-line option for the smallest liver tumors — a potentially practice-changing result if the interim data hold.

Lung cancer features prominently as well, with two distinct studies. The I-SABR trial reported six-year overall survival data for patients with early-stage non-small cell lung cancer who received nivolumab, an immune checkpoint inhibitor, following stereotactic ablative radiotherapy. The rationale behind combining radiation with immunotherapy rests on a compelling biological idea: radiation can kill tumor cells in ways that release tumor antigens and may prime the immune system, potentially turning a localized treatment into a systemic one. Randomized evidence on whether that synergy improves long-term survival in early-stage disease, presented by Joe Chang, MD, PhD, MS, FASTRO, is among the most closely watched data of the meeting.

The second lung cancer study addresses a frustrating clinical scenario. In the phase 2 MDT-Bridge study, patients with resectable or borderline resectable stage IIB–IIIB non-small cell lung cancer who became unresectable during neoadjuvant treatment were treated with chemoradiotherapy followed by consolidation durvalumab. For these patients, the surgical option disappears mid-treatment, and the study — presented as a late-breaking abstract by Andrea Filippi, MD — explores whether a bridge of definitive chemoradiation plus immunotherapy can salvage outcomes when surgery is no longer on the table. The strategy reflects a broader shift in thoracic oncology, where the boundaries between surgery, radiation and drug therapy are increasingly treated as fluid rather than fixed.

Prostate cancer and pediatric oncology round out the highlight list. NRG Oncology GU003 reported five-year results of a phase 3 trial comparing hypofractionated with conventional postprostatectomy radiotherapy, presented by Mark Buyyounouski, MD, MS, FASTRO — another test of whether shorter schedules can match longer ones in the adjuvant setting after surgery. And from the Children’s Oncology Group, Nadia Laack, MD, MS, presented results from AEWS1221 examining stereotactic body radiation therapy and comprehensive metastasis-directed therapy for patients with Ewing sarcoma, an aggressive cancer of bone and soft tissue that primarily strikes children and young adults. Metastasis-directed therapy — using precisely targeted radiation to attack individual sites of spread — represents one of the most conceptually ambitious ideas in modern radiation oncology, and applying it within a cooperative group pediatric trial marks an important step in bringing that approach to younger patients.

Taken together, the highlighted studies sketch a portrait of a field in transition. Shorter, more convenient treatment schedules are being validated across tumor types. Particle therapy is being put to the test in randomized trials rather than relying on dosimetric theory alone. Radiation is being combined with immunotherapy in ways that exploit its biological, not just its physical, effects. And the field is confronting directly who gets access to its advances, and why. ASTRO, the world’s largest professional society dedicated to advancing radiation medicine with 11,000 members, notes that radiation therapy is integral to 40 percent of cancer cures worldwide and that more than one million Americans receive radiation treatment for cancer each year. The data presented in Boston this week — and the conversations they are designed to spark — will help determine what those treatments look like for the next generation of patients.

Subject of Research: Clinical trial highlights in radiation oncology presented at the 2026 ASTRO Annual Meeting

Article Title: Additional research highlights from the 2026 ASTRO Annual Meeting

Article References: Additional research highlights from the 2026 ASTRO Annual Meeting. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ASTRO 2026, radiation oncology, hypofractionation, proton therapy, hepatocellular carcinoma, SBRT, nivolumab, immunotherapy, Ewing sarcoma, breast cancer, lung cancer, health equity